Literature DB >> 15133672

Ulcerative colitis: conservative management and long-term effects.

Tanja Kühbacher1, Stefan Schreiber, Ulrich R Fölsch.   

Abstract

Ulcerative colitis is characterized by chronic inflammation of the colon. Typical symptoms are diarrhoea, rectal bleeding, abdominal pain and fever. The aetiology of the disease is unclear. The inflammation can be localized in the rectum or can extend to the left side or the whole colon. Treatment for induction and remission maintenance depends on the severity and extension of mucosal inflammation. Topical 5-aminosalicylates have been shown in studies to be the treatment of choice in mild to moderate ulcerative colitis. Oral 5-aminosalicylates can be used in distal, mild and moderate ulcerative colitis and for remission maintenance. For patients with a more extended or severe inflammation, oral or i.v. corticosteroids should be used. Patients with severe and/or chronic disease require immunosuppressive therapy with azathioprine or 6-mercaptopurine. For patients with severe, chronic, refractory disease, cyclosporine i.v. can be used. If no response to treatment is seen, proctocolectomy should be considered. Biological agents such as beta-Interferon seem to be effective in mild to moderately ulcerative colitis, but further studies have to be performed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133672     DOI: 10.1007/s00423-004-0477-8

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  13 in total

Review 1.  [Standard therapy of ulcerative colitis. Evidence- and consensus-based recommendations].

Authors:  K Herrlinger; K Fellermann; E F Stange
Journal:  Internist (Berl)       Date:  2002-11       Impact factor: 0.743

Review 2.  Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis.

Authors:  L Sutherland; D Roth; P Beck; G May; K Makiyama
Journal:  Cochrane Database Syst Rev       Date:  2000

3.  Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.

Authors:  A B Hawthorne; R F Logan; C J Hawkey; P N Foster; A T Axon; E T Swarbrick; B B Scott; J E Lennard-Jones
Journal:  BMJ       Date:  1992-07-04

4.  Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.

Authors:  W Kruis; E Schütz; P Fric; B Fixa; G Judmaier; M Stolte
Journal:  Aliment Pharmacol Ther       Date:  1997-10       Impact factor: 8.171

5.  Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.

Authors:  B J Rembacken; A M Snelling; P M Hawkey; D M Chalmers; A T Axon
Journal:  Lancet       Date:  1999-08-21       Impact factor: 79.321

6.  Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.

Authors:  Paolo Gionchetti; Fernando Rizzello; Ulf Helwig; Alessandro Venturi; Karen Manon Lammers; Patrizia Brigidi; Beatrice Vitali; Gilberto Poggioli; Mario Miglioli; Massimo Campieri
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

7.  Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study.

Authors:  S Nikolaus; P Rutgeerts; R Fedorak; A H Steinhart; G E Wild; D Theuer; J Möhrle; S Schreiber
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

8.  Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.

Authors:  R A Kozarek; D J Patterson; M D Gelfand; V A Botoman; T J Ball; K R Wilske
Journal:  Ann Intern Med       Date:  1989-03-01       Impact factor: 25.391

9.  Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up.

Authors:  A Chun; R M Chadi; B I Korelitz; T Colonna; J B Felder; M H Jackson; E H Morgenstern; S D Rubin; A G Sacknoff; G M Gleim
Journal:  Inflamm Bowel Dis       Date:  1998-08       Impact factor: 5.325

10.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

Authors:  C S J Probert; S D Hearing; S Schreiber; T Kühbacher; S Ghosh; I D R Arnott; A Forbes
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more
  4 in total

Review 1.  Practical guidelines for the treatment of inflammatory bowel disease.

Authors:  T Kuhbacher; U R Fölsch
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

2.  Effects of an Oral Supplementation of Germinated Barley Foodstuff on Serum CRP Level and Clinical Signs in Patients with Ulcerative Colitis.

Authors:  Zeinab Faghfoori; Rahebeh Shakerhosseini; Lida Navai; Mohammad Hossein Somi; Zeinab Nikniaz; Alireza Abadi
Journal:  Health Promot Perspect       Date:  2014-07-12

3.  Proteomic analysis of colonic mucosal tissue from tuberculous and ulcerative colitis patients.

Authors:  Seong-Chun Kwon; Kyung Jong Won; Seoung Hyo Jung; Kang Pa Lee; Dong-Youb Lee; Eun-Seok Park; Bokyung Kim; Gab Jin Cheon; Koon Hee Han
Journal:  Korean J Physiol Pharmacol       Date:  2012-06-26       Impact factor: 2.016

Review 4.  Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links.

Authors:  Abdo Jurjus; Assad Eid; Sahar Al Kattar; Marie Noel Zeenny; Alice Gerges-Geagea; Hanine Haydar; Anis Hilal; Doreid Oueidat; Michel Matar; Jihane Tawilah; Inaya Hajj Hussein; Pierre Schembri-Wismayer; Francesco Cappello; Giovanni Tomasello; Angelo Leone; Rosalyn A Jurjus
Journal:  BBA Clin       Date:  2015-11-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.